Case Reports Open access

Complement inhibition: a therapeutic turning point in the treatment of recurrent myelitis in a patient with systemic lupus erythematosus

Authors

Published
13 November 2026
Issue
Early Access
Section
Case Reports
DOI
10.4081/reumatismo.2026.2409

Abstract

Systemic lupus erythematosus (SLE) and neuromyelitis optica spectrum disorder (NMOSD) are autoimmune diseases that have been reported to coexist. We describe the case of a 61-year-old woman with long-standing SLE and Sjögren’s disease who developed recurrent longitudinally extensive transverse myelitis associated with concomitant NMOSD. Despite treatment with glucocorticoids, plasma exchange, and rituximab, she experienced multiple neurological relapses, with persistent positivity of anti-aquaporin-4 antibodies and magnetic resonance imaging findings consistent with NMOSD, while SLE remained clinically inactive. Therefore, we initiated treatment with an anti-C5 monoclonal antibody for relapse prevention. To our knowledge, this is the first reported case of a patient with coexisting SLE and NMOSD treated with an anti-C5 monoclonal antibody, remaining relapse-free throughout a 22-month follow-up period.

Keywords

References

  1. Conti F, Spinelli FR, Colafrancesco S, Truglia S, Ceccarelli F, Fattapposta F, et al. Acute longitudinal myelitis following Cryptococcus laurentii pneumonia in a patient with systemic lupus erythematosus. Lupus 2015; 24: 94-7. DOI: https://doi.org/10.1177/0961203314554848
  2. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52. DOI: https://doi.org/10.1212/WNL.33.11.1444
  3. Schwartz N, Stock AD, Putterman C. Neuropsychiatric lupus: new mechanistic insight and future treatment directions. Nat Rev Rheumatol 2019; 15: 137-52. DOI: https://doi.org/10.1038/s41584-018-0156-8
  4. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis 2019; 78: 1151-9. DOI: https://doi.org/10.1136/annrheumdis-2018-214819
  5. Theodoridou A, Settas L. Demyelination in rheumatic diseases. Postgrad Med J 2008; 84: 127-32. DOI: https://doi.org/10.1136/jnnp.2005.075861
  6. Lavalle C, Pizarro S, Drenkard C, Sánchez-Guerrero J, Alarcón-Segovia D. Transverse myelitis: a manifestation of systemic lupus erythematosus strongly associated with antiphospholipid antibodies. J Rheumatol 1990; 17: 34-7.
  7. Li XY, Xiao HB, Pai P. Myelitis in systemic lupus erythematosus. J Clin Neurosci 2017; 44: 18-22. DOI: https://doi.org/10.1016/j.jocn.2017.06.003
  8. Jarius S, Wildemann B. The history of neuromyelitis optica. J Neuroinflammation 2013; 10: 8. DOI: https://doi.org/10.1186/1742-2094-10-8
  9. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85: 177-89. DOI: https://doi.org/10.1212/WNL.0000000000001729
  10. Cruz RA, Chaudhary S, Guevara M, Meltzer E. Neuromyelitis optica spectrum disorders (NMOSD) and connective tissue disease (CTD): an update for the rheumatologist. Curr Rheumatol Rep 2021; 23: 33. DOI: https://doi.org/10.1007/s11926-021-01000-2
  11. Martín-Nares E, Hernandez-Molina G, Fragoso-Loyo H. Aquaporin-4-IgG positive neuromyelitis optica spectrum disorder and systemic autoimmune diseases overlap syndrome: a single-center experience. Lupus 2019; 28: 1302-11. DOI: https://doi.org/10.1177/0961203319877255
  12. Wingerchuk DM, Weinshenker BG. The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Mult Scler 2012; 18: 5-10. DOI: https://doi.org/10.1177/1352458511431077
  13. April RS, Vansonnenberg E. A case of neuromyelitis optica (Devic’s syndrome) in systemic lupus erythematosus. Neurology 1975; 26: 1066-70. DOI: https://doi.org/10.1212/WNL.26.11.1066
  14. Raya AA, Raya SA. Neuromyelitis optica spectrum disorders (NMOSD) and systemic lupus erythematosus (SLE): dangerous duo. Int J Rheum Dis 2024; 17: e14973.
  15. Kümpfel T, Giglhuber K, Aktas O, Ayzenberg I, Bellmann-Strobl J, Häußler V, et al. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: attack therapy and long-term management. J Neurol 2024; 271: 141-76. DOI: https://doi.org/10.1007/s00415-023-11910-z
  16. Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med 2019; 381: 614-25. DOI: https://doi.org/10.1056/NEJMoa1900866
  17. Pittock SJ, Fujihara K, Palace J, Berthele A, Kim HJ, Oreja-Guevara C, et al. Eculizumab monotherapy for NMOSD: data from PREVENT and its open-label extension. Mult Scler. 2022; 28: 480-6. DOI: https://doi.org/10.1177/13524585211038291
  18. Singh P, Gao X, Kleijn HJ, Bellanti F, Pelto R. Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Neuromyelitis Optica Spectrum Disorder. Front Neurol 2021; 12: 696387. DOI: https://doi.org/10.3389/fneur.2021.696387
  19. Traboulsee A, Greenberg BM, Bennett JL, Szczechowski L, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: A randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol 2020; 19: 402−412. DOI: https://doi.org/10.1016/S1474-4422(20)30078-8

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.

PlumX Metrics

License

Copyright (c) 2026 the Author(s)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.